Clinical trials: Chemotherapy Symptoms

Uterine Fibroids

A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

• Completed
• Age: 20 years and older
• Phase 3
• Results posted

The purpose of this study is to evaluate the efficacy and safety of Relugolix (TAK-385) in patients having pain symptoms associated with uterine fibroids.

Trial name

NCT02655224

Testing

Relugolix

Where

11 sites in Japan

Volunteers

65 people

Sponsor

Takeda